Despite the widespread use of PD-1 blockade in cancer immunotherapy, the systemic impact of PD-1 blockade on the development and function of diverse leukocyte subsets other than intratumoral antigen-specific T lymphocytes remains largely unknown. The gene discussed is PDCD1; the disease is cancer.